| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Glycolysis pathway, AMP-activated protein kinase (AMPK), and cellular energy metabolism. D-Allose inhibits cell growth by decreasing glycolysis and intracellular ATP levels, and prolongs AMPK activation. Also inhibits cancer cell growth via suppression of glucose metabolism and induction of oxidative stress.
|
|---|---|
| ln Vitro |
In vitro, D-Allose inhibits growth of head and neck cancer cells by decreasing glycolysis and ATP levels, and through prolonged AMPK activation. Antiproliferative in glioblastoma cells associated with reduced cell division frequency. Antioxidant, anti-inflammatory, and immunosuppressive effects. Investigated as anticancer agent, especially in combination with radiation and metabolic agents.
|
| ln Vivo |
D-Allose shows anticancer effects in head and neck and bladder cancer models. Intraperitoneal administration inhibits tumor energy pathway and synergizes with radiation. Oral administration shows antitumor effects in bladder cancer. In colitis-associated carcinogenesis mouse model, reduces inflammation and tumor formation. No side effects observed. Promising for cancer therapy, especially combined with first-line drugs.
|
| Enzyme Assay |
No specific receptor binding; D-Allose affects cellular metabolism. For metabolic assays: (1) Seed cancer cells in 96-well plates. (2) Treat with D-Allose (1-100 mM) for 24-72 h. (3) Measure glucose uptake using 2-NBDG fluorescent probe. (4) Measure intracellular ATP using CellTiter-Glo or ATP Bioluminescence Assay. (5) For AMPK activation: treat cells with D-Allose (10-100 mM) for 0-12 h, lyse, Western blot for phospho-AMPK (Thr172) and total AMPK.
|
| Cell Assay |
(1) Seed cancer cells (head and neck, glioblastoma, bladder) at 5,000-10,000/well. (2) Treat with D-Allose (1-100 mM) for 24-72 h. (3) Add MTT/CCK-8, measure OD, calculate IC50. (4) For apoptosis: treat 48 h, stain Annexin V-FITC/PI, flow cytometry. (5) For cell cycle: treat 24-48 h, fix in 70% ethanol, stain with PI (50 ug/mL)+RNase A (100 ug/mL), FACS. (6) For glycolysis: measure lactate production by assay kit. (7) For combination: treat with D-Allose (1-50 mM) plus ionizing radiation (2-10 Gy), assess clonogenic survival.
|
| Animal Protocol |
(1) For head and neck cancer: use BALB/c nude mice bearing FaDu or CAL27 xenografts (100-150 mm3). (2) Administer D-Allose IP (0.5-2 g/kg) daily for 14-21 days in sterile saline/PBS. (3) For radiation combination: give D-Allose (1-2 g/kg IP) 1 h before local tumor irradiation (2-5 Gy daily ×5). (4) Monitor tumor volume twice weekly. (5) For bladder cancer: oral D-Allose (1-2 g/kg) daily for 2-4 weeks. (6) For colitis-associated carcinogenesis: treat AOM/DSS mice with D-Allose (0.5-1 g/kg PO daily) for 12 weeks. (7) At endpoint, collect tumors for IHC (Ki-67, cleaved caspase-3), TUNEL, and Western blot (AMPK, p-AMPK, glycolysis markers).
|
| ADME/Pharmacokinetics |
Highly soluble in water (≥200 mg/mL). For cell culture, dissolve directly in medium, filter sterilize. For in vivo, dissolve in sterile saline or PBS at 100-200 mg/mL (pH7.0-7.4); for IV use 50-100 mg/mL. Storage: powder at -20degC for 3 years; solution at 4degC for 2 weeks, -20degC for 6 months. PK in rodents (IP 1 g/kg): Cmax 2-5 mM, t1/2 1-2 h, rapid renal clearance. Oral bioavailability 20-40%.
|
| Toxicity/Toxicokinetics |
In vitro: CCK-8 on normal cells (fibroblasts, HEK293) with D-Allose up to 200 mM, 48 h, no significant cytotoxicity. In vivo: acute oral LD50 in mice >10 g/kg; IV LD50 >5 g/kg. High doses (>2 g/kg IP) cause transient osmotic diarrhea and mild weight loss. No significant hepatotoxicity, nephrotoxicity, or neurotoxicity. No side effects in preclinical studies.
|
| Additional Infomation |
Aldose-hexose is a hexose with a (potential) aldehyde group at one end. It is both an aldose and a hexose. D-mannose has been reported in peas (Pisum sativum), and relevant data are available. It is a major energy source for organisms. It exists naturally, in a free state in fruits and other parts of plants. It is used medicinally to replenish body fluids and nutrients. See also: Polydextrose (note moved to); D-allose (note moved to); D-mannose (note moved to)... See more...
D-Allose is a rare sugar, C-3 epimer of D-glucose, produced enzymatically from D-allulose or D-psicose. Exhibits potent anticancer effects via glycolysis inhibition, ATP depletion, and AMPK activation. Absorbed from intestine, excreted unchanged in urine, minimal metabolism. Low-calorie sugar. Not FDA-approved as a drug; investigated for cancer therapy, especially with radiation. Also studied for food industry and clinical treatment. |
| Molecular Formula |
C6H12O6
|
|---|---|
| Molecular Weight |
180.16
|
| Exact Mass |
180.063
|
| CAS # |
2595-97-3
|
| Related CAS # |
D-Allose-13C;70849-28-4;D-Allose-13C-1;D-Allose-13C-2
|
| PubChem CID |
24749
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
527.1±50.0 °C at 760 mmHg
|
| Melting Point |
148-150ºC(lit.)
|
| Flash Point |
286.7±26.6 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
-3.17
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
12
|
| Complexity |
138
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C([C@@H]1[C@H]([C@H]([C@H](C(O1)O)O)O)O)O
|
| InChi Key |
GZCGUPFRVQAUEE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2
|
| Chemical Name |
2,3,4,5,6-pentahydroxyhexanal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~555.06 mM)
H2O :~100 mg/mL (~555.06 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (555.06 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5506 mL | 27.7531 mL | 55.5062 mL | |
| 5 mM | 1.1101 mL | 5.5506 mL | 11.1012 mL | |
| 10 mM | 0.5551 mL | 2.7753 mL | 5.5506 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
